Navigation Links
Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
Date:5/4/2011

CRANBURY, N.J., May 4, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the first quarter ended March 31, 2011. The Company also highlighted recent and upcoming milestones, including an update on patient enrollment in the ongoing Phase 3 study of its lead program Amigal™ (migalastat HCl) for Fabry disease.

Development Pipeline Highlights

  • Enrollment in Phase 3 Amigal study (Study 011) is nearing completion and is expected to be fully enrolled in 2Q11 or 3Q11
  • Phase 2 Amigal extension study continues to provide encouraging safety and renal function data following up to four years of treatment
  • Patient dosing commenced in Phase 2 study of Amigal co-administered with enzyme replacement therapy (ERT) for Fabry disease
  • Moving forward with Phase 2 study of AT2220 (1-deoxynojirimycin HCI) co-administered with ERT for Pompe disease

  • Matthew R. Patterson, President and Acting Chief Executive Officer of Amicus Therapeutics said, "We continue to make excellent progress across all parts of our business. Our Phase 3 study of Amigal for Fabry disease remains our top priority and we are close to enrolling the final patient. We are also excited to have dosed our first patient in a Phase 2 study evaluating pharmacological chaperones co-administered with ERT. We see this approach as an important extension of our science and a validation of the broader therapeutic potential of our pharmacological chaperone technology. Amicus is in a position of strategic and financial strength due to the positive momentum of our development programs and the successful collaboration with our partner, GSK Rare Diseases. Our team is focused on the achievement of multiple key milestones during 2011."

    First Qua
    '/>"/>

    SOURCE Amicus Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
    3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
    4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
    5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
    6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
    7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
    8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
    9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
    10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
    11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
    (Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
    (Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
    Breaking Medicine Technology:It's Better Hearing Month 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2
    ... 16, Uroplasty, Inc. (Nasdaq: UPI ), ... innovative proprietary products to treat voiding dysfunctions, announced today ... Jiwani, Uroplasty,s Vice President and CFO, will present the ... Hunter Securities Inaugural Healthcare Conference at 3:30  PM PDT ...
    ... a crippling disease worldwide, with an estimated eight million sufferers ... a suit of rusty armour," with unrelenting, razor-like pain. ... reverse the degenerative condition. However a discovery made ... hold the key to not only halting the degenerative process, ...
    Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2New Hope For Joint Pain Sufferers 2New Hope For Joint Pain Sufferers 3
    (Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 The opportunity for ... full life are the motivating forces behind The Fairy Godmother ... psychologist and author Amy L. Stark. , The inspiration for ... girl next door comes from Stark’s desire to be a ... been a fairy godmother to my neighbors’ children since they ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
    (Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
    (Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
    Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
    ... Highlights, - Revenue for the first quarter was $480.6 million, up 7.6% from ... ... ("FOI") grew 7.2% for the twelve, months ended March 31, 2008 over ... was $38.6 million, or $0.38,per outstanding common share, a 19% increase over the ...
    ... project as innovative in terms of energy efficiency and ... awarded nearly $27 million in funding for a new ... (USC). USC was one of 12 California institutions considered ... million to build stem cell research facilities throughout California. ...
    ... May 8, 2008 at 2:00 pm ET, MISSION ... ENSG ), the parent company of the Ensign(TM) ... today reported results for the first quarter of fiscal ... ) Highlights of the First Quarter Include:, ...
    ... 7 Conseco, Inc. (NYSE: CNO ),today reported ... set a new quarterly sales record with an increase ... Prieur said. "This performance included,an 11% increase at Bankers ... increase in total sales including new product offerings) of ...
    ... , Ottawa (May 7, 2008) The Honourable ... the Canadian Institutes of Health Research (CIHR) for 764 ... Minister Clement was joined by Dr. Patrick McGrath, a ... neonatologist and CIHR-funded researcher from the University of Alberta, ...
    ... 7 Dr. Hugo Stephenson, founder and ... drug safety, today,presented new insight about the ... the U.S. Food and Drug Administration (FDA). ... (rosuvastatin),Lipitor (atorvastatin), and Zocor (simvastatin) all warn ...
    Cached Medicine News:Health News:Brookdale Announces First Quarter 2008 Results 2Health News:Brookdale Announces First Quarter 2008 Results 3Health News:Brookdale Announces First Quarter 2008 Results 4Health News:Brookdale Announces First Quarter 2008 Results 5Health News:Brookdale Announces First Quarter 2008 Results 6Health News:Brookdale Announces First Quarter 2008 Results 7Health News:Brookdale Announces First Quarter 2008 Results 8Health News:Brookdale Announces First Quarter 2008 Results 9Health News:Brookdale Announces First Quarter 2008 Results 10Health News:Brookdale Announces First Quarter 2008 Results 11Health News:Brookdale Announces First Quarter 2008 Results 12Health News:Brookdale Announces First Quarter 2008 Results 13Health News:Brookdale Announces First Quarter 2008 Results 14Health News:Brookdale Announces First Quarter 2008 Results 15Health News:Brookdale Announces First Quarter 2008 Results 16Health News:Brookdale Announces First Quarter 2008 Results 17Health News:Brookdale Announces First Quarter 2008 Results 18Health News:Brookdale Announces First Quarter 2008 Results 19Health News:Brookdale Announces First Quarter 2008 Results 20Health News:Brookdale Announces First Quarter 2008 Results 21Health News:Brookdale Announces First Quarter 2008 Results 22Health News:USC receives nearly $27 million in funding for new stem cell research facility 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 3Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 4Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 5Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 6Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 7Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 8Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 9Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 10Health News:Conseco Reports First Quarter Results 2Health News:Conseco Reports First Quarter Results 3Health News:Conseco Reports First Quarter Results 4Health News:Conseco Reports First Quarter Results 5
    Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification....
    The Pneumatic Consulting Otoscope provides two viewing lenses for dual observation of the tympanic membrane. Sealed system for pneumnatic otoscopy and rotatable head for left- and right-sided viewin...
    Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
    ... to laser treatment of AMD patients ... compares to the Opal Photoactivator from,Lumenis. ... (verteporfin for injection) therapy, the Opal ... any other laserfeatures,that ensure the highest ...
    Medicine Products: